Business
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.
About this update from Sanofi Sa
[{"type":"text","content":"SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.","length":548,"tagName":"p"},{"type":"image","alt":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","displaySize":"","headline":null,"caption":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xC7KVbaMcGEd2k2sIIuNYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNA--/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/w_XEdYC2SuVPL0XqB0caPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIxMw--/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133}},"href":"https://mma.prnewswire.com/media/1063194/inhibrx_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Upcoming Milestones","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ozekibart (INBRX-109)","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"We expect to submit the Biologics License Application ("BLA") for ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma to the U.S. Food and Drug Administration ("FDA") early in the second quarter of 2026;","length":257,"tagName":"p"}]},{"val":[{"type":"text","content":"We plan to announce progression-free survival ("PFS") data for the Phase 1/2 colorectal cancer expansion cohort in the second quarter of 2026; and","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"We plan to meet with the FDA to discuss accelerated approval for Ewing Sarcoma and fourth line colorectal cancer in the secon...